Tradestie Institutional Equity Comparison Engine

SRZN vs ATYR โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ATYR Overall Edge

ATYR Captures Institutional Edge (2โ€“1 Pillars ยท 2โ€“5 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to aTyr Pharma, Inc. Common Stock (ATYR) driven by superior Momentum & Technical, Options & Structure while SRZN counters with relative strength in Growth & Margin. Fundamentally, SRZN trades at N/M Forward P/E with -485.4% operating margin (+408.6% YoY revenue) versus ATYR at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, SRZN sits in CONSOLIDATION (5th %ile IV; Dealer Gamma Walls on Pro) against ATYR sits in UNCLASSIFIED (36th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
SRZN N/M vs ATYR N/M Fwd P/E
Growth & Margin Winner SRZN
Op Margin -485.4% vs 0.0% ยท YoY +408.6% vs +0.0%
Momentum & Technical Winner ATYR
1Y +130.6% vs +541.4% ยท 52W Pos 69% vs 60%
Options & Structure Winner ATYR
CONSOLIDATION (5th %ile IV) vs UNCLASSIFIED (36th %ile IV)
SRZN NASDAQ
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$29.93
-7.38% 1D
Market Cap $602.5M
1M Return +25.57%
1Y Return +130.62%
Forward P/E N/M
Unified AI Score
33.2 / 100 SELL
Tech 50.0 Fund 34.0 Flow 65.0 Mom 40.0
ATYR NASDAQ
aTyr Pharma, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$4.83
-7.82% 1D
Market Cap $15.6M
1M Return +2713.05%
1Y Return +541.43%
Forward P/E N/M
Unified AI Score
34.3 / 100 SELL
Tech 50.0 Fund 36.0 Flow 69.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: SRZN +130.62% ATYR +541.43% Spread: +410.81 pp (ATYR Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period SRZN Revenue ATYR Revenue SRZN Op. Margin ATYR Op. Margin Margin Edge
FY2019 N/A $0M N/A -5445.0% ATYR
FY2020 N/A $10M N/A -152.2% ATYR
FY2022 $10M $10M -354.7% -446.8% SRZN
FY2023 N/A $0M N/A -15557.8% ATYR
FY2024 $10M $0M -239.7% -28899.6% SRZN
FY2025 $0M $0M -1210.6% -40856.3% SRZN

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: SRZN (5) vs ATYR (2)
Institutional Metric SRZN ATYR Criterion Row Winner
Market Capitalization Scale $602.5M $15.6M Larger Scale SRZN
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +408.6% +0.0% Higher Growth SRZN
Operating Margin (TTM) Profitability -485.4% 0.0% Higher Margin ATYR
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -62.8% -93.7% Higher ROE SRZN
52-Week Range Position Momentum 69% ($12โ€“$38) 60% ($0โ€“$8) Stronger Trend SRZN
Beta / 30D Volatility Risk Regime 1.28ฮฒ ยท 66% Vol -9.57ฮฒ ยท 13806% Vol Lower Realized Risk SRZN
Unified Institutional Score Composite Signal 33.2 / 100 (SELL) 34.3 / 100 (SELL) Higher Composite ATYR

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full SRZN vs ATYR Buy Guide
SRZN CONSOLIDATION
38d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 5th %ile
IV Regime Compressed (<25th %ile)
Live SRZN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ATYR UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 36th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live ATYR Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither SRZN nor ATYR registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.